Document Detail


Pathophysiology and pharmacology of the cardiac "late sodium current.".
MedLine Citation:
PMID:  18662720     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The "late sodium current" (I(NaL)) is a sustained component of the fast Na+ current of cardiac myocytes and neurons. As recently appreciated, common neurological and cardiac conditions are associated with abnormal I(NaL) enhancement, which may contribute to the pathogenesis of both electrical and contractile dysfunction. For this reason, I(NaL) has become an appealing pharmacological target, with a potentially broad range of therapeutic indications. The recent approval by the FDA of an I(NaL) blocker (ranolazine) for clinical use justifies the increased interest in I(NaL) as a pathogenic mechanism and the rapid evolution of the information concerning it. The review focuses on cardiac aspects of I(NaL) enhancement; it deals with the origin of I(NaL), with its pathophysiological role and with the consequences of its pharmacological modulation. Both basic aspects and clinical evidence are discussed.
Authors:
Antonio Zaza; Luiz Belardinelli; John C Shryock
Publication Detail:
Type:  Journal Article; Review     Date:  2008-07-01
Journal Detail:
Title:  Pharmacology & therapeutics     Volume:  119     ISSN:  0163-7258     ISO Abbreviation:  Pharmacol. Ther.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-09-08     Completed Date:  2009-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905840     Medline TA:  Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  326-39     Citation Subset:  IM    
Affiliation:
Dipartimento di Biotecnologie e Bioscienze, Università Milano-Bicocca Milano (IT), Italy. antonio.zaza@unimib.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetanilides / pharmacology
Action Potentials / drug effects
Animals
Heart Conduction System / drug effects*,  metabolism,  physiopathology
Humans
Models, Biological
Piperazines / pharmacology
Sodium / metabolism*
Sodium Channel Blockers / pharmacology*
Sodium Channels / physiology*
Chemical
Reg. No./Substance:
0/Acetanilides; 0/Piperazines; 0/Sodium Channel Blockers; 0/Sodium Channels; 110445-25-5/ranolazine; 7440-23-5/Sodium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Developmental lead exposure impairs extinction of conditioned fear in young adult rats.
Next Document:  Navigated transcranial magnetic stimulation and computed electric field strength reduce stimulator-d...